Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 14/20 | 0.66 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.49 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12896204 | 0.85 | NOTUM (0.70) | NOTUMTLR8ALDH1A1HPGDMAPK1 | |
| SCHEMBL27967176 | 0.81 | TLR8 (0.58) | NOTUMTLR8ALDH1A1HPGDMAPK1 | |
| SCHEMBL1186047 | 0.80 | NOTUM (1.00) | NOTUMTLR8ALDH1A1HPGDMAPK1 | |
| SCHEMBL21795694 | 0.78 | NOTUM (0.75) | NOTUMTLR8ALDH1A1HPGDMAPK1 | |
| SCHEMBL24282140 | 0.77 | NOTUM (0.62) | NOTUMTLR8ALDH1A1HPGDMAPK1 | |
| SCHEMBL10835887 | 0.77 | NOTUM (0.62) | NOTUMTLR8ALDH1A1HPGDMAPK1 | |
| SCHEMBL30413279 | 0.76 | NOTUM (0.63) | NOTUMALDH1A1HPGDMAPK1KDM4E | |
| SCHEMBL23451945 | 0.76 | NOTUM (0.63) | NOTUMALDH1A1HPGDMAPK1KDM4E | |
| SCHEMBL23451672 | 0.75 | KDM4E (0.44) | DRD1ALDH1A1HPGDKDM4ELMNA | |
| SCHEMBL23451501 | 0.74 | NOTUM (1.00) | NOTUMALDH1A1HPGDMAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634391-B2 | Compounds which are inhibitors of Notum | UCL BUSINESS LTD (GB) | 2023-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634391-B2 | Compounds which are inhibitors of Notum | NOTUM, GOT2, GOT1 | NOTUM 1/4885TLR8 4095/4885DRD1 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.